Viz.ai is applying artificial intelligence in healthcare. They have created a suite of AI powered products that identify large vessel occlusion (LVO) strokes from CT angiograms and alert on-call stroke teams. Their HIPPA compliant software allows stroke teams to consult in real time on their mobile phones, increasing treatment speed.
The company received De Novo clearance from the FDA in 2018 for their Viz LVO platform, becoming the first-ever computer-aided triage and notification platform, and recently received further 510(k) approval for VIZ CTP (for cerebral image analysis). It sells its suite of products to hospital networks and medical institutions, including Mount Sinai in New York and Swedish Health System in Denver. Viz.ai has two issued patents and more pending to support their efforts.
After being named one of Forbes's 50 most promising AI companies in September and one of CB Insights's 150 most promising digital health startups earlier this month, the company is putting the industry on notice. Now, they have announced a $50 million Series B funding. With lead investor Greenoaks, there is further participation from Threshold Ventures and CRV, along with existing investors Google Ventures and Kleiner Perkins.